Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
Drug Target Review
JUNE 6, 2023
Our goal is to design and develop potentially first- and best-in-class molecules to deliver meaningful clinical benefit across a wide range of cancers, including tumour types where immunotherapies are not yet approved or have not shown efficacy. References: M; LWR. Interleukin 12: Still a promising candidate for tumor immunotherapy?
98 
Let's personalize your content